insights_auto
Why is 7CA up 2.88%?
Dive Deeperchevron_right
7CA:FRA
Camurus AB
€58.95
arrow_upward
+2.88%(+1.65) 1D
Oct 20, 8:05:56 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 7CA...
Open
€58.95
High
€58.95
Low
€58.95
Mkt. cap
39.24B
Avg. vol.
20.00
Volume
0.00
52-wk high
€67.15
52-wk low
€40.60
No. of employees
316
Open
€58.95
High
€58.95
Low
€58.95
Mkt. cap
39.24B
Avg. vol.
20.00
Volume
0.00
52-wk high
€67.15
52-wk low
€40.60
No. of employees
316
News stories
From web sources and news partners
ChartMill
·
1 hour ago
S&P 500 Unusual Volume Movers for October 20
TradingView
·
1 hour ago
S&P 500 Could Hit 8,300 By May 2027, Says Morgan Stanley Investment Chief Predicting ‘Final Innings’ Of Stock Market Correction
Yahoo Finance
·
1 hour ago
Ciena (CIEN): Is the AI-Optical Boom Enough to Carry It Into the S&P 500?
Insider Monkey
·
52 minutes ago
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?
Profile
Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap.
Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures. The company provides nanoscale drug-delivery systems for development of high-value therapeutics. Wikipedia
About Camurus AB
CEOFredrik Tiberg
Employees316
Founded1991
Headquarters-
SectorPharmaceutical industry
Websitecamurus.com